The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Chronic hepatitis C patients with sustained virological response (SVR) after treatment may still be at risk of hepatocellular carcinoma (HCC), a new study reports. Risk factors include a lower platelet count, cirrhosis and elevated aspartate aminotransferase (AST) levels.
Combined treatment with aspirin and clopidogrel is at least as safe as prolonged aspirin use regarding the risk of cancer, according to a recent study, which supports the hypothesis that clopidogrel use may reduce cancer incidence.
Two Swedish national registry studies presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 suggest no increased cancer risk for rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs (bDMARDs), including tumour necrosis factor (TNF) inhibitors.
The experimental targeted therapy, enasidenib, an oral selective inhibitor of mutated IDH2 enzymesdeveloped for the treatment of acute myeloid leukaemia (AML), has demonstrated maturation of blasts to neutrophils with resultant prolongation of survival in treatment-resistant patients with mutant-IDH2AML in an early trial.
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
A psychological intervention, Conquer Fear, may help alleviate fear of cancer recurrence (FCR) in cancer survivors, according to a study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Three vs 6 months of adjuvant oxaliplatin-based chemotherapy may be sufficient for colon cancer with low risk of recurrence and has the advantage of fewer side effects, according to the IDEA* trial which pooled data from six phase III trials.
The second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) dacomitinib improved progression-free survival (PFS) by an additional 5 months compared with gefitinib in patients with EGFR-positive non-small cell lung cancer (NSCLC), according to results of the open-label, phase III ARCHER 1050* trial.
Smoking rates are worryingly high in Asia, with the number of adult smokers reaching 121 million, half of whom live in Indonesia, according to an expert who addressed an audience of oncologists at the recent Asia Pacific Lung Cancer Conference 2016 in Chiang Mai, Thailand.
More biomarkers should be included in the standard molecular testing for lung adenocarcinoma to improve patients’ prognosis and survival, results of the LCMC II (Lung Cancer Mutation Consortium II) study suggest.